A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004
Compared to Placebo for the Prevention of Clostridium difficile Infection (CDI) in
Hospitalized Patients receiving IV ceftriaxone with a Diagnosis of a Lower Respiratory Tract
Infection (LRTI).